Aurobindo Pharma Results

Strong Q4 performance, debt reduction show Aurobindo Pharma in good health

Despite an over 150 per cent rise since March lows, the stock can see more gains

Aurobindo Pharma Q3 net marginally down at Rs 705 cr, revenue up 12%

According to a filing with the bourses, revenues from operations during the quarter under review was up by nearly 12 per cent to Rs 5,895 crore. It was Rs 5,269.7 crore in Q3 FY19.

Aurobindo Pharma aims to become debt-free in the next three years

The company's net debt decreased by $71 million quarter-on-quarter to $522 million at the end of September 2019 against $593 million at the end of June 2019

Aurobindo consolidated Q2 profit before tax up 5.9% at Rs 904 crore

Gross profit margin slipped to 20.8% during the quarter under review from 21.6% in the year-ago previous quarter owing to higher expenditure, which grew by 19%

Healthy outlook: Aurobindo Pharma posts Rs 5.95 billion net profit in Q3

Aurobindo Pharma's reported profit after tax at Rs 5.95 billion for the December quarter (Q3), up a mere three per cent year-on-year, may have disappointed the street as the stock fell 2.4 per cent to Rs 602 on Thursday, but a look at the core performance and future prospects provide comfort. For one, Aurobindo had to re-measure its US deferred tax assets and liabilities based on the new tax law and also recognise a one-time charge of Rs 664 million in Q3. Thus, its net profit came below estimates of Rs 6.63 billion.Overall performance, however was healthy led by growing US and Europe sales. The US (44 per cent of topline) and Europe (27 per cent) businesses grew by 9.4 per cent and 37 per cent, respectively over the year ago period. Thus, overall revenues at Rs 43.36 billion (up 11 per cent year-on-year) came ahead of estimates of Rs 42.56 billion. Operating profit at Rs 10.26 billion was up 14.6 per cent year-on-year, leading to an 80 basis points expansion in margins. Although ARV .

Aurobindo Pharma Q1 profit dips 11% at Rs 518 cr on low US sales, GST

BS ReporterHyderabad, 9 August: Hyderabad-based Aurobindo Pharma Limited has reported a 11.4 percent decline in consolidated net profit at Rs 518.5 crore for the quarter ended June, 2017 in the absence of growth from formulations business during the period.The revenues from operations that include both the formulations and active pharmaceutical ingredients (API) segments has decreased 2.3 percent to Rs 3,678.7 crore for the quarter under review as compared to Rs 3,766.6 crore in the corresponding quarter previous year.For the first time in recent quarters the company's formulations business in the US slowed down during the quarter. Despite the launch of 15 products, including three injectables,during the quarter, the US revenues from this segment declined by 50 basis points at Rs 1,694.9 crore as compared to Rs 1,703.9 crore in the year ago period. However, on the constant currency basis the US revenues registered a 3.2 percent growth during the period, according to the company.On ..